Biotech RadarJobs updated

COMPANY

NuvOx Therapeutics

HQ: Tucson, AZ source · nuvoxtherapeutics.com ↗

Clinical Phase 3

Keywords: glioblastoma respiratory stroke Ischemic Stroke Glioblastoma Multiforme Respiratory Distress Syndrom Hypoxic Conditions Mild Respiratory Distress NanO2TM NanO₂ NVX-108

Location: Tucson, AZ · source · Oct 15, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

  1. Trial start —: Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic source ↗
  2. Trial start Phase 1: A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress source ↗
  3. Trial start Phase 2/Phase 3: NanO2 for Large Vessel Occlusion Stroke source ↗
  4. Trial start Phase 2: A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM source ↗
  5. Trial start I: A Phase Ib/II in Patients With Acute Ischemic Stroke source ↗
  6. Trial start Phase 1: The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT03862430A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBMPhase 2Active, not recruitingMar 31, 2023Jun 30, 2027 (estimated)
NCT07748299NuvOx Expanded AccessNot listedAvailableNot listedNot listed
NCT07417774Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen TherapeuticNot listedEnrolling by invitationDec 8, 20252027-12 (estimated)
NCT06658535A Dose Escalation Study of NanO2 in Patients With Mild Respiratory DistressPhase 1RecruitingMar 13, 20252026-12 (estimated)
NCT05389748NanO2 for Large Vessel Occlusion StrokePhase 2/Phase 3Unknown status (ClinicalTrials.gov)Apr 1, 2023Apr 1, 2025 (estimated)
NCT02963376A Phase Ib/II in Patients With Acute Ischemic StrokeICompletedFeb 1, 2017Jul 9, 2018 (actual)
NCT02189109The Effects of NVX-108 as a Radiation Sensitizer in GlioblastomaPhase 1Completed2014-05Aug 31, 2017 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback